7
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Efeitos de tratamento combinado de alendronato de sódio, atorvastatina cálcica e ipriflavona na osteoporose induzida com dexametasona em ratas Translated title: Effects of combined treatment of alendronate of sodium, calcic atorvastatin and ipriflavone in osteoporosis induced with dexamethasone in female rats

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          O objetivo deste trabalho foi estudar a influência das combinações: bifosfonato (alendronato de sódio) + estatina (atorvastatina cálcica), bifosfonato (alendronato de sódio) + flavonóide (ipriflavona) e estatina (atorvastatina cálcica) + flavonóide (ipriflavona) em ratas com osteoporose induzida pelo glicocorticóide dexametasona. As influências das associações dessas substâncias foram pesquisadas pela análise de testes dos marcadores bioquímicos de remodelação óssea, tais como, cálcio e fósforo sérico, fosfatase alcalina óssea e por exames histomorfométricos, caracterizando a densidade trabecular óssea. Através da avaliação da densidade trabecular óssea foi possível verificar o aumento da mesma em todos os tratamentos efetuados. Ressaltando-se, ainda, que as associações contendo alendronato de sódio apresentaram elevadas taxas de restauração tecidual óssea, alcançando valores superiores aos do grupo dos animais normais. Os marcadores bioquímicos não apresentaram resultados estatisticamente significativos, não fornecendo subsídios para o diagnóstico e acompanhamento da osteoporose. No entanto, a avaliação histomorfométrica permitiu a análise estática e dinâmica, bem como detecção de alterações teciduais na unidade metabólica óssea, particularmente, no osso trabecular.

          Translated abstract

          The objective of this work was to study the influence of the combinations: biphosphonate (alendronate of sodium) + statin (calcic atorvastatin), biphosphonate (sodium alendronate) + flavonoid (ipriflavone) and statin (calcic atorvastatin) + flavonoid (ipriflavone) in female rats with osteoporosis induced by the glucocorticoid dexamethasone. The influence of the combinations of those drugs was observed through tests of the biochemical markers of bone remodeling, such as, levels of serum calcium and phosphorus and bone alkaline phosphatase and through histomorphometric exam, visualizing the bone trabecular density. Through the evaluation of the bone trabecular density it was possible to verify the clear increase in any group of treated animals. The combinations with biphosphonate presented high rates of bone tissue restoration, reaching higher values than those of normal animals. The results obtained with biochemical markers were not statistically significant and did not subsidies the diagnosis and the follow of the osteoporosis. However, the histomorphometric evaluation allowed us the static and dynamic analyses as well as detection of tissue alterations in the bone metabolic unit, particularly in the trabecular bone.

          Related collections

          Most cited references41

          • Record: found
          • Abstract: found
          • Article: not found

          Glucocorticoid osteoporosis--mechanisms and management.

          IR Reid (1997)
          Glucocorticoids are potent osteopenic agents, producing negative calcium and bone balance via actions at many sites. The most significant adverse effects of glucocorticoid drugs on the skeleton are probably a direct inhibition of matrix synthesis by the osteoblast, reductions in calcium absorption in both the gut and the renal tubule, and the production of hypogonadism, particularly in men. Reductions in bone density of 10-40% result, the loss being more marked in trabecular bone and in patients receiving a high cumulative dose of the steroid. Fractures occur in about 30% of individuals who take these drugs for an average of 5 years. Bone loss is reversible when glucocorticoid treatment is withdrawn. Bone density can also be increased by sex hormone replacement in those with demonstrable deficiency, by bisphosphonates, and possibly by vitamin D metabolites. All patients treated with glucocorticoids for more than 6 months should be considered for bone densitometry and be offered appropriate drug treatment if values are towards the lower end of the young normal range or if there is already evidence of fractures occurring after minimal trauma. With this approach, the significant morbidity associated with steroid osteoporosis might be substantially avoided.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            The influence of multidentate organic phosphonates on the crystal growth of hydroxyapatite.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Biochemical markers in the assessment of bone disease.

              As the mean age of our population increases, increasing attention has been paid to the diseases associated with aging, including diseases of the skeleton such as osteoporosis. Effective means of treating and possibly preventing such skeletal disorders are emerging, making their early recognition an important goal for the primary care physician. Although bone density measurements and skeletal imaging studies remain of primary diagnostic importance in this regard, a large number of assays for biochemical markers of bone formation and resorption are being developed that promise to complement the densitometry measurements and imaging studies, providing an assessment of the rates of bone turnover and an earlier evaluation of the effects of therapy. In this review, emphasizing the recent literature, the major biochemical markers currently in use or under active investigation are described, and their application in a number of diseases of the skeleton including osteoporosis is evaluated.
                Bookmark

                Author and article information

                Contributors
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Role: ND
                Journal
                rbcf
                Revista Brasileira de Ciências Farmacêuticas
                Rev. Bras. Cienc. Farm.
                Divisão de Biblioteca e Documentação do Conjunto das Químicas da Universidade de São Paulo (São Paulo )
                1516-9332
                March 2006
                : 42
                : 1
                : 99-107
                Affiliations
                [1 ] Universidade Federal de Viçosa Brazil
                [2 ] Universidade Federal de Viçosa Brazil
                [3 ] Universidade Federal de Ouro Preto
                Article
                S1516-93322006000100011
                10.1590/S1516-93322006000100011
                27110827-0025-4c7b-8fe5-8934ca161bf0

                http://creativecommons.org/licenses/by/4.0/

                History
                Product

                SciELO Brazil

                Self URI (journal page): http://www.scielo.br/scielo.php?script=sci_serial&pid=1516-9332&lng=en
                Categories
                PHARMACOLOGY & PHARMACY

                Pharmacology & Pharmaceutical medicine
                Osteoporosis,Atorvastatin,Ipriflavone,Osteoporose,Dexametasona,Alendronato,Atorvastatina,Ipriflavona,Associação de fármacos,Dexamethasone,Alendronate,Drug combinations

                Comments

                Comment on this article